Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms.
about
Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and OriginsEpigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursorsRecent technological advances in using mouse models to study ovarian cancer.A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.Culture models to define key mediators of cancer matrix remodeling.Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface.Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.Current state of biomarkers in ovarian cancer prognosis.A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium.Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines.PRKCI promotes immune suppression in ovarian cancer.STAT3/PIAS3 levels serve as "early signature" genes in the development of high-grade serous carcinoma from the fallopian tube.Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.
P2860
Q27320720-D3DB57CC-BC31-422F-958D-892E1912AE7EQ30491616-40A6DF6F-6298-4CA2-8071-2A42904782ACQ36097633-A54447E8-529C-4FB4-962E-3C021318B1B7Q37244240-17AC8DC2-7C0C-4597-8791-EA4A2B32E32DQ37581537-80FDAF59-B197-4C4C-87ED-809B0C5641D5Q37642705-FBB597CB-B6A1-4680-87A3-42A3EF75A277Q37676502-4DE9B282-1985-4E01-9C8E-C719D4873178Q37688456-AAFF149A-7207-428F-95CD-2676CD0AA588Q37739177-B1264DC1-F57D-4365-BC38-CE856A5B7879Q38628964-08D4BCF4-1394-4AC8-B22F-E276F26AD382Q41612110-122D4934-2BC1-45BB-9243-F7D6EC099758Q41631736-710CD2B1-EE0B-4702-AF16-C9BCA3D411D7Q42838218-69A829D1-F0C0-4C6A-82F8-A686F07ACA6FQ47154650-FEDA510B-88D6-4CBA-B215-A5E3C077BD0AQ50020012-E0E75DEC-9DBA-4E00-982E-B7F8B4DAE16CQ51633169-55B20296-9598-4A1B-BEA5-1D2EB8F35340
P2860
Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Modeling High-Grade Serous Car ...... Better Experimental Platforms.
@en
Modeling High-Grade Serous Car ...... Better Experimental Platforms.
@nl
type
label
Modeling High-Grade Serous Car ...... Better Experimental Platforms.
@en
Modeling High-Grade Serous Car ...... Better Experimental Platforms.
@nl
prefLabel
Modeling High-Grade Serous Car ...... Better Experimental Platforms.
@en
Modeling High-Grade Serous Car ...... Better Experimental Platforms.
@nl
P2860
P356
P1476
Modeling High-Grade Serous Car ...... Better Experimental Platforms.
@en
P2093
Paul Michael Jones
Ronny Drapkin
P2860
P356
10.3389/FONC.2013.00217
P577
2013-08-26T00:00:00Z